Hi, my name is Lori Ann Blakeley.
Welcome to my Web site developed and maintained on my behalf by my father, Larry Blakeley. http://www.royblakeley.name/larry_blakeley/larryblakeley_photos_jpeg.htm
My father also manages the following Web sites:
Larry Blakeley (Contact Info: larry at larryblakeley.com)
Major Roy James Blakeley (USAF - KIA) (December 10, 1928 - July 22, 1965) - my grandfather
Leslie Blakeley Adkins - my older sister
Evan Blakeley- my younger brother
A Web page for giving notices of interest to visitors here. http://www.loriblakeley.name/notices_of_interest.htm
Various letters and notes here. http://www.loriblakeley.name/various_notes_letters.htm
What my brother, Evan Blakeley is up to with his baseball. http://www.evanblakeley.name
My mother's walking club for the students at Cockrell Hill Elementary School, DeSoto, Texas http://www.loriblakeley.name/article_dallas_morning_news_jackie_blakeley20070601.htm
****************************************************************
T-cell receptor genes therapy-based clinical trial currently being conducted (melanoma only at this point in time; February 6, 2005) by Steven A. Rosenberg, M.D., Ph.D. http://ccr.cancer.gov/staff/staff.asp?profileid=5757 of the Surgery Branch http://ccr.cancer.gov/labs/lab.asp?labid=93 of the National Cancer Institute.
The Surgery Branch of the National Cancer Institute here http://ccr.cancer.gov/labs/lab.asp?labid=93
Email exchange with Matthias Theobald, M.D. http://www.lori.blakeley.name/email_exchange_matthias_theobald20050204.htm,
José Carreras Leukemia Foundation Professor of Medicine,
Department of Hematology and Oncology,
Johannes Gutenberg-University
Langenbeckstr, Mainz / Germany regarding the article, recent report "Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR," http://www.immunity.com/content/article/abstract?uid=PIIS1074761304003826 Matthias Theobald et al, Immunity http://www.immunity.com/, Volume 22, 117-129, January, 2005
Note: This article/research report was purchased for $30 from Elsevier at the following Web page http://dx.doi.org/10.1016/j.immuni.2004.12.005 and is copyrighted by Elsevier Inc.
and is very scientific and leading edge.
But, some generalities can be learned by most from this article and the email exchange - some of which are the following:
- the date of the article;
- the name, address, and facilities that the authors are based out of;
- the area of study (i.e. T-cell receptor genes; broad-spectrum cancer immunotherapeutics - tumor - and leukemia-associated antigens (TAA);
- who has protocols/clinical trials for this aproach and what type of cancer is being studied in these trials.
- this report is promising and gives you a general vision of exciting and promising alternative therapy.